Tokyo, Sept. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059173) titled 'Repeated Application Study of RETISOME IDB Facial Serum' on Sept. 30.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Self control
Primary Sponsor:
Institute - JC Dermatology Laboratory Co., LTD.
Condition:
Condition - healthy adults
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate improvements in skin and stratum corneum condition following facial application of a serum containing Retisome IDB.
Basic objectives2 - Efficacy
Intervention:
Interventions/Control_1 - Apply the serum twice a day to all faces for 8 weeks.
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - ･Healthy males and females in the age more than 20 and less than 60 years.
･Particpants who are concerned about sagging and wrinkles of skin.
･Particpants who are concerned about spots and dullness of skin.
･Particpants who are concerned about dry skin.
･During the examination period, Particpants who can avoid sun exposure and implement UV protection measures.
Key exclusion criteria - ･Participants with alcoholic.
･During the examination period, Participants who plan to begin new beauty treatment (such as esthetic treatment and aesthetic medicine.) and have newly started it within the past two months.
･During the examination period, Participants who plan to change their usual lifestyle habits. (such as starting or stopping a diet and changing sleep habits.)
･Participants with skin conditions. (such as face skin inflammation.)
･Participants who participated in other studies one month prior to the date of consent or scheduled to participate in studies.
･Participants who are pregnant, breastfeeding, or planning pregnancy during the study period.(including immediately after childbirth.)
･Participants with cosmetics allergies or a history of them.
･Participants with hormone replacement therapy.
･Participants with taking treatment a disease and medicine.
Target Size - 10
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 09 Month 05 Day
Date of IRB - 2025 Year 09 Month 12 Day
Anticipated trial start date - 2025 Year 10 Month 14 Day
Last follow-up date - 2025 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067682
Disclaimer: Curated by HT Syndication.
